Oruka Therapeutics
ORKA
22 hedge funds and large institutions have $17.5M invested in Oruka Therapeutics in 2016 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
38% more funds holding
Funds holding: 16 → 22 (+6)
1.68% less ownership
Funds ownership: 68.09% → 66.41% (-1.7%)
56% less capital inflows, than outflows
Capital inflows: $391K | Capital outflows: $890K
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Panagora Asset Management
Boston,
Massachusetts
|
+$265K |
| 2 |
BlackRock Fund Advisors
San Francisco,
California
|
+$42.2K |
| 3 |
Goldman Sachs
New York
|
+$37.7K |
| 4 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$35.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$5.18K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
-$739K |
| 2 |
Royce & Associates
New York
|
-$92.5K |
| 3 |
Virtu KCG Holdings
New York
|
-$54K |
| 4 |
Walleye Trading
New York
|
-$2.96K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$2.22K |
ORKA Hedge Fund Activity: Q2 2016 in Review
22 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q2 2016, worth a combined $17.5M — down 18% from $21.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ORKA positions and 1 closed out — a net gain of 6 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Panagora Asset Management, opening a new position worth an estimated $265K. The largest seller was RA Capital Management, cutting an estimated $739K.
- 22 institutional investors held Oruka Therapeutics (ORKA) as of Q2 2016, up from 16 in Q1 2016.
- Funds reported $17.5M of Oruka Therapeutics stock for Q2 2016, down 18% quarter-over-quarter.
- 7 funds opened new Oruka Therapeutics positions in Q2 2016 and 1 closed out, a net change of +6 holders.
- The largest Oruka Therapeutics buyer in Q2 2016 was Panagora Asset Management, an estimated $265K added.
- The largest Oruka Therapeutics seller in Q2 2016 was RA Capital Management, an estimated $739K sold.
Based on aggregated 13F filings for Q2 2016.